Drug profile · INN
deutivacaftor / tezacaftor / vanzacaftor
ALYFTREK
deutivacaftor / tezacaftor / vanzacaftor (ALYFTREK) is an FDA-listed pharmaceutical active ingredient. Associated with Vertex Pharmaceuticals (Australia) Pty..
Drug details — deutivacaftor / tezacaftor / vanzacaftor
- Class
- Respiratory system (R07)
- Route
- —
- Patents
- 20
- Programs
- 2
- Data quality
- 0.89
Quick answer
deutivacaftor / tezacaftor / vanzacaftor (ALYFTREK) is an FDA-listed pharmaceutical active ingredient. Associated with Vertex Pharmaceuticals (Australia) Pty..
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11951212
Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
granted -
US 11639347
Modulators of ATP-binding cassette transporters
granted -
US 11578062
Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
granted -
US 11564916
Pharmaceutical composition and administrations thereof
granted -
US 10646481
Pharmaceutical composition and administrations thereof
granted -
US 10239867
Modulators of ATP-binding cassette transporters
granted -
US 10206877
Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
granted -
US 10081621
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
granted -
US 10058546
Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof
granted -
US 10022352
Modulators of ATP-binding cassette transporters
granted -
US 9974781
Modulators of ATP-binding cassette transporters
granted -
US 9931334
Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
granted -
US 9670163
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
granted -
US 9012496
Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
granted -
US 8754224
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
granted -
US 8623905
Modulators of ATP-binding cassette transporters
granted -
US 8598181
Modulators of ATP-binding cassette transporters
granted -
US 8415387
Modulators of ATP-binding cassette transporters
granted -
US 8410274
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
granted -
US 8354427
Modulators of ATP-binding cassette transporters
granted
Frequently asked questions
What is deutivacaftor / tezacaftor / vanzacaftor?
deutivacaftor / tezacaftor / vanzacaftor (ALYFTREK) is an FDA-listed pharmaceutical active ingredient. Associated with Vertex Pharmaceuticals (Australia) Pty..
What is the brand name for deutivacaftor / tezacaftor / vanzacaftor?
ALYFTREK is a marketed brand name for deutivacaftor / tezacaftor / vanzacaftor. Check FDA Drugs@FDA for the current US label holder and prescribing information.